Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Colchicine for coronary plaque stabilization after NSTEMI
ACTRN12618000809235Phase 2Completed
- Sponsor
- South Australian Health and Medical Research Institute
- Start
- Dec 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in acute coronary syndrome (ACS), coronary arteriosclerosis and Non-ST-segment elevation myocardial infarction (NSTEMI) comparing Colchicine with Placebo (2 arms). Primary endpoint: Percentage change in coronary plaque minimum fibrous cap thickness. Started Dec 2018; status: completed.
02
Drugs
colchicine
03
Conditions
acute coronary syndrome (ACS)coronary arteriosclerosisNon-ST-segment elevation myocardial infarction (NSTEMI)
Beyond the preview
Go deeper on ACTRN12618000809235.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12618000809235.